European Union - English - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressants - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 75 mg / 0.83 ml - risankizumab - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of activepsoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 150 mg / 1 ml - risankizumab - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of activepsoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 150 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - concentrate for solution for infusion - risankizumab 60 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

Canada - English - Health Canada

abbvie corporation - risankizumab - solution - 90mg - risankizumab 90mg - misc. skin and mucous membrane agents

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - risankizumab - injection, solution - risankizumab 75mg/0.83ml

Canada - English - Health Canada

abbvie corporation - risankizumab - solution - 150mg - risankizumab 150mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

abbvie corporation - risankizumab - solution - 150mg - risankizumab 150mg - misc. skin and mucous membrane agents

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - risankizumab - injection, solution - risankizumab 150mg